Capital Fund Management S.A. Buys New Holdings in Supernus Pharmaceuticals Inc (SUPN)

Capital Fund Management S.A. bought a new position in shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) in the fourth quarter, HoldingsChannel reports. The fund bought 90,866 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,621,000.

Several other institutional investors have also added to or reduced their stakes in the company. State Street Corp grew its holdings in shares of Supernus Pharmaceuticals by 3.1% during the second quarter. State Street Corp now owns 1,397,484 shares of the specialty pharmaceutical company’s stock worth $60,230,000 after buying an additional 42,165 shares in the last quarter. Rice Hall James & Associates LLC boosted its position in shares of Supernus Pharmaceuticals by 8.0% during the 4th quarter. Rice Hall James & Associates LLC now owns 1,322,614 shares of the specialty pharmaceutical company’s stock valued at $52,706,000 after acquiring an additional 98,297 shares during the last quarter. Acadian Asset Management LLC boosted its position in shares of Supernus Pharmaceuticals by 2.0% during the 4th quarter. Acadian Asset Management LLC now owns 1,280,179 shares of the specialty pharmaceutical company’s stock valued at $51,013,000 after acquiring an additional 24,491 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of Supernus Pharmaceuticals by 22.7% during the 4th quarter. Wells Fargo & Company MN now owns 755,422 shares of the specialty pharmaceutical company’s stock valued at $30,105,000 after acquiring an additional 139,838 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its position in shares of Supernus Pharmaceuticals by 17.7% during the 3rd quarter. Ameriprise Financial Inc. now owns 681,792 shares of the specialty pharmaceutical company’s stock valued at $27,271,000 after acquiring an additional 102,341 shares during the last quarter. 98.20% of the stock is owned by institutional investors and hedge funds.

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 20,000 shares of the company’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $48.04, for a total value of $960,800.00. Following the transaction, the vice president now owns 32,500 shares of the company’s stock, valued at $1,561,300. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Victor Vaughn sold 5,750 shares of the company’s stock in a transaction dated Friday, January 12th. The shares were sold at an average price of $45.03, for a total transaction of $258,922.50. Following the completion of the transaction, the vice president now directly owns 15,094 shares in the company, valued at approximately $679,682.82. The disclosure for this sale can be found here. Insiders sold 165,750 shares of company stock worth $7,133,973 in the last ninety days. 6.70% of the stock is currently owned by corporate insiders.

Supernus Pharmaceuticals Inc (NASDAQ SUPN) opened at $38.35 on Monday. Supernus Pharmaceuticals Inc has a 1 year low of $24.65 and a 1 year high of $50.04. The company has a market cap of $1,970.00, a PE ratio of 34.86 and a beta of 1.08.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 19.85% and a return on equity of 26.62%. The company had revenue of $80.40 million for the quarter, compared to analysts’ expectations of $78.74 million. The business’s revenue was up 41.5% compared to the same quarter last year. research analysts predict that Supernus Pharmaceuticals Inc will post 1.07 earnings per share for the current fiscal year.

Several brokerages have recently weighed in on SUPN. BidaskClub raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 11th. Zacks Investment Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research report on Wednesday, January 10th. Cowen set a $50.00 price target on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, October 23rd. B. Riley reissued a “buy” rating and set a $50.00 price target on shares of Supernus Pharmaceuticals in a research report on Monday, November 20th. Finally, Janney Montgomery Scott raised shares of Supernus Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $47.00 price target on the stock in a research report on Monday, December 4th. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $51.36.

WARNING: This news story was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://ledgergazette.com/2018/02/19/capital-fund-management-s-a-buys-new-holdings-in-supernus-pharmaceuticals-inc-supn.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply